Australia markets closed

Pacira BioSciences, Inc. (PCRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
58.53+0.40 (+0.69%)
As of 12:29PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close58.13
Open58.14
Bid58.43 x 1100
Ask58.54 x 800
Day's range57.38 - 58.72
52-week range27.46 - 59.93
Volume253,195
Avg. volume750,487
Market cap2.465B
Beta (5Y monthly)1.28
PE ratio (TTM)N/A
EPS (TTM)-0.00
Earnings date05 Nov 2020 - 09 Nov 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est62.85
  • GlobeNewswire

    Pacira BioSciences Reports Second Quarter 2020 Financial Results and Business Update

    \-- EXPAREL average daily sales return to year-over-year growth in month of June 2020 -- \-- Conference call today at 8:30 a.m. ET --PARSIPPANY, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain management options, today reported financial results for the second quarter of 2020.“We are very pleased to report that since the peak of the impact from COVID-19 in April, we’ve seen a steady and continued increase in EXPAREL sales. This is a testimony to the resolve of our physician partners who are dedicated to ensuring that patients receive their much-needed surgeries, particularly in the ambulatory setting,” said Dave Stack, chairman and chief executive officer of Pacira BioSciences. “This pandemic has accelerated the shift of inpatient procedures to the 23-hour stay environment and we are well positioned to lead the way with our innovative opioid alternatives.”“Today, we are in a stronger position than ever as we wind down our partnership with DePuy Synthes and take full ownership of the EXPAREL franchise. Our recent financing strengthens our financial foundation and supports our strategy to expand our footprint in non-opioid pain management and regenerative health solutions while simultaneously ramping the top and bottom lines,” continued Mr. Stack.Second Quarter 2020 Financial Results * Total revenues were $75.5 million in the second quarter of 2020, a 26% decrease versus the $102.6 million reported for the second quarter of 2019. * EXPAREL net product sales were $73.0 million in the second quarter of 2020, a 26% decrease versus the $98.9 million reported for the second quarter of 2019. * Second quarter 2020 iovera° net product sales were $1.4 million, a 31% decrease versus the $2.0 million reported for the second quarter of 2019. * Sales of bupivacaine liposome injectable suspension to a third-party licensee for use in veterinary practice were $0.8 million in the second quarter of 2020, compared to $0.9 million in the second quarter of 2019. * Second quarter 2020 royalty revenues were $0.3 million, compared to $0.8 million in the second quarter of 2019. * Total operating expenses were $82.7 million in the second quarter of 2020, compared to $97.3 million in the second quarter of 2019. * Research and development (R&D) expenses were $13.6 million in the second quarter of 2020, compared to $17.8 million in the second quarter of 2019. R&D expenses include $6.1 million and $6.8 million of product development and manufacturing capacity expansion costs in the second quarters of 2020 and 2019, respectively. * Selling, general and administrative (SG&A) expenses were $43.3 million in the second quarter of 2020, compared to $49.1 million in the second quarter of 2019. * GAAP net loss was $7.3 million, or $0.17 per share (basic and diluted), in the second quarter of 2020, compared to GAAP net income of $2.7 million, or $0.07 per share (basic) and $0.06 per share (diluted), in the second quarter of 2019. * Non-GAAP net income was $5.0 million, or $0.12 per share (basic and diluted), in the second quarter of 2020, compared to non-GAAP net income of $17.5 million, or $0.42 per share (basic) and $0.41 per share (diluted), in the second quarter of 2019. * Adjusted EBITDA was $8.5 million in the second quarter of 2020, versus adjusted EBITDA of $21.9 million in the second quarter of 2019. * Pacira ended the second quarter of 2020 with cash, cash equivalents, short-term and long-term investments (“cash”) of $335.1 million. Cash used in operations was $15.6 million in the second quarter of 2020, compared to cash provided by operations of $22.8 million in the second quarter of 2019. * Pacira had 42.2 million basic weighted average shares of common stock outstanding in the second quarter of 2020. * For non-GAAP measures, Pacira had 42.9 million diluted weighted average shares of common stock outstanding in the second quarter of 2020.See “Non-GAAP Financial Information” below.Recent Highlights * Preliminary net product sales for July 2020.  Today the company also reported preliminary unaudited net product sales of EXPAREL and iovera° of $38.1 million and $0.8 million, respectively, for the month of July 2020. Given the rapidly changing variables related to the COVID-19 pandemic, the company does not have sufficient visibility to accurately forecast the impact of the pandemic and is currently not providing full-year 2020 financial guidance. In order to provide greater transparency, the company plans to report monthly intra-quarter unaudited net product sales until it has gained sufficient visibility around the impacts of COVID-19.   * FDA acceptance of sNDA for EXPAREL use in pediatric patients. In August 2020, Pacira announced the U.S. Food and Drug Administration (FDA) has accepted the submission of its supplemental new drug application (sNDA) seeking expansion of the EXPAREL label to include single-dose infiltration to provide postsurgical analgesia in children aged six and over. The expected action date by the FDA under the Prescription Drug User Fee Act (PDUFA) is March 22, 2021.   * Issuance of $402.5 million aggregate principal amount of 0.750% convertible senior notes due 2025. In July 2020, Pacira issued $402.5 million in aggregate principal amount of convertible senior notes due 2025 in a private placement. Pacira used approximately $211.1 million of the net proceeds to repurchase $185.0 million aggregate principal amount of its outstanding 2.375% Convertible Senior Notes due 2022. Pacira intends to use the remainder of the net proceeds from the offering for general corporate purposes, including working capital, research and development expenditures and the license or acquisition of complementary products and/or technologies.   * Conclusion of EXPAREL agreement with DePuy Synthes. In July 2020, Pacira announced the conclusion of its agreement with DePuy Synthes Sales Inc. to jointly market and promote the use of EXPAREL for orthopedic procedures in the United States. Under this collaboration, which began in January 2017, DePuy Synthes field representatives, specializing in joint reconstruction, spine, sports medicine, trauma and cranio-maxillofacial procedures, collaborate with the Pacira field teams to support EXPAREL use and education in orthopedic surgical settings. In addition to partnering with DePuy Synthes in support of orthopedic surgical procedures, Pacira field representatives have remained the overall EXPAREL account managers and commercial leads for soft tissue surgeons, anesthesiologists, and ambulatory surgery centers.Today’s Conference Call and Webcast ReminderThe Pacira management team will host a conference call to discuss the company’s financial results and recent developments today, Thursday, August 6, 2020, at 8:30 a.m. ET. To participate in the conference call, dial 1-877-845-0779 and provide the passcode 3276818. International callers may dial 1-720-545-0035 and use the same passcode. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the “Events” page on the Pacira website at investor.pacira.com.For those unable to participate in the live call, a replay will be available at 1-855-859-2056 (domestic) or 1-404-537-3406 (international) using the passcode 3276818. The replay of the call will be available for one week from the date of the live call. The webcast will be available on the Pacira website for approximately two weeks following the call.Non-GAAP Financial InformationThis press release contains financial measures that do not comply with U.S. generally accepted accounting principles (GAAP), such as non-GAAP net income, non-GAAP net income per share, non-GAAP cost of goods sold, non-GAAP gross margins, non-GAAP research and development (R&D) expense, non-GAAP selling, general and administrative (SG&A) expense and adjusted EBITDA, because such measures exclude acquisition-related charges (gains) and product discontinuation costs; stock-based compensation; amortization of debt discount; amortization of acquired intangible assets, an income tax benefit and step-up in basis of inventory in connection with the acquisition of MyoScience, Inc. and gain on investment.These measures supplement the company’s financial results prepared in accordance with GAAP. Pacira management uses these measures to better analyze its financial results, estimate its future cost of goods sold, gross margins, R&D expense and SG&A expense outlook for 2020 and to help make managerial decisions. In management’s opinion, these non-GAAP measures are useful to investors and other users of our financial statements by providing greater transparency into the operating performance at Pacira and its future outlook. Such measures should not be deemed to be an alternative to GAAP requirements or a measure of liquidity for Pacira. Non-GAAP measures are also unlikely to be comparable with non-GAAP disclosures released by other companies. See the tables below for a reconciliation of GAAP to non-GAAP measures, including adjusted EBITDA.About Pacira BioSciencesPacira BioSciences, Inc. (Nasdaq: PCRX) is a leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for health care practitioners and their patients. The company’s long-acting local analgesic, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, Pacira acquired the iovera°® system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.About EXPARELEXPAREL (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks. The product combines bupivacaine with DepoFoam, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting. By utilizing the DepoFoam platform, a single dose of EXPAREL delivers bupivacaine over time, providing significant reductions in cumulative pain scores with up to a 78 percent decrease in opioid consumption; the clinical benefit of the opioid reduction was not demonstrated. Additional information is available at www.EXPAREL.com.Important Safety Information for PatientsEXPAREL should not be used in obstetrical paracervical block anesthesia. In studies where EXPAREL was injected into the wound, the most common side effects were nausea, constipation, and vomiting. In studies where EXPAREL was injected near a nerve, the most common side effects were nausea, fever, and constipation. EXPAREL is not recommended to be used in patients younger than 18 years old or in pregnant women. Tell your healthcare provider if you have liver disease, since this may affect how the active ingredient (bupivacaine) in EXPAREL is eliminated from your body. EXPAREL should not be injected into the spine, joints, or veins. The active ingredient in EXPAREL: can affect your nervous system and your cardiovascular system; may cause an allergic reaction; may cause damage if injected into your joints.About iovera°The iovera° system is used to destroy tissue during surgical procedures by applying freezing cold. It can also be used to produce lesions in peripheral nervous tissue by the application of cold to the selected site for the blocking of pain. It is also indicated for the relief of pain and symptoms associated with osteoarthritis of the knee for up to 90 days. In one study, the majority of the patients suffering from osteoarthritis of the knee experienced pain and system relief beyond 150 days.1 The iovera° system’s “1×90” Smart Tip configuration (indicating one needle which is 90 mm long) can also facilitate target nerve location by conducting electrical nerve stimulation from a separate nerve stimulator. The iovera° system is not indicated for treatment of central nervous system tissue.Important Safety InformationThe iovera° system is contraindicated for use in patients with the following: Cryoglobulinemia; Paroxysmal cold hemoglobinuria; cold urticaria; Raynaud’s disease; open and/or infected wounds at or near the treatment line. Potential complications: As with any surgical treatment that uses needle-based therapy, there is potential for temporary site-specific reactions, including but not limited to: bruising (ecchymosis); swelling (edema); inflammation and/or redness (erythema); pain and/or tenderness; altered sensation (localized dysesthesia). Typically, these reactions resolve with no physician intervention. Patients may help the healing process by applying ice packs to the affected sites, and by taking over-the-counter analgesics.Forward-Looking StatementsAny statements in this press release about the company’s future expectations, plans, outlook, projections and prospects, and other statements containing the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may,” “will,” “would,” “could,” “can” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to: the impact of the worldwide COVID-19 (Coronavirus) pandemic and related global economic conditions on our business and results of operations; the cost and timing of an early termination   1Radnovich, R. et al. “Cryoneurolysis to treat the pain and symptoms of knee osteoarthritis: a multicenter, randomized, double-blind, sham-controlled trial.” Osteoarthritis and Cartilage (2017) p1-10. payment to DePuy Synthes Sales, Inc.; the success of the company’s sales and manufacturing efforts in support of the commercialization of EXPAREL; the rate and degree of market acceptance of EXPAREL; the size and growth of the potential markets for EXPAREL and the company’s ability to serve those markets; the company’s plans to expand the use of EXPAREL to additional indications and opportunities, and the timing and success of any related clinical trials for EXPAREL; the ability to realize anticipated benefits and synergies from the acquisition of MyoScience; the ability to successfully integrate iovera° and any other future acquisitions into the company’s existing business; the commercial success of iovera°; the rate and degree of market acceptance of iovera°; the size and growth of the potential markets for iovera° and our ability to serve those markets; our plans to expand the use of iovera° to additional indications and opportunities, and the timing and success of any related clinical trials for iovera°; and other factors discussed in the “Risk Factors” of the company’s most recent Annual Report on Form 10-K and in other filings that the company periodically makes with the SEC. In addition, the forward-looking statements included in this press release represent the company’s views as of the date of this press release. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements, and as such the company anticipates that subsequent events and developments will cause its views to change. However, while the company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date of this press release.(Tables to Follow) Pacira BioSciences, Inc. Condensed Consolidated Balance Sheets (in thousands) (unaudited)      June 30, 2020 December 31, 2019 ASSETS    Current assets:      Cash, cash equivalents and short-term investments$335,053   $291,950     Accounts receivable, net44,013   47,530     Inventories, net66,690   58,296     Prepaid expenses and other current assets18,328   10,781     Total current assets455,823   408,557   Long-term investments8,261   64,798   Fixed assets, net113,297   104,681   Right-of-use assets, net77,799   38,124   Goodwill99,547   99,547   Intangible assets, net100,454   104,387   Equity investment and other assets10,930   10,971     Total assets$866,111   $831,065        LIABILITIES AND STOCKHOLDERS’ EQUITY    Current liabilities:      Accounts payable$9,160   $12,799     Accrued expenses47,684   70,427     Lease liabilities7,620   4,935     Contingent consideration4,504   18,179     Income taxes payable1,615   1,333     Total current liabilities70,583   107,673   Convertible senior notes314,182   306,045   Lease liabilities73,888   40,938   Contingent consideration16,326   19,963   Other liabilities2,984   1,502   Total stockholders’ equity388,148   354,944     Total liabilities and stockholders’ equity$866,111   $831,065       Pacira BioSciences, Inc. Condensed Consolidated Statements of Operations (in thousands, except per share amounts) (unaudited) Three Months Ended Six Months Ended  June 30, June 30,  2020 2019 2020 2019  Net product sales:          EXPAREL$73,046    $98,868    $174,315    $189,482      Bupivacaine liposome injectable suspension775    921    1,981    1,213      Total EXPAREL / bupivacaine liposome   injectable suspension net product sales73,821    99,789    176,296    190,695      iovera°1,395    2,035    3,665    2,035     Total net product sales75,216    101,824    179,961    192,730     Royalty revenue289    780    1,228    1,187      Total revenues75,505    102,604    181,189    193,917             Operating expenses:          Cost of goods sold22,305    25,201    52,037    52,505      Research and development13,620    17,827    29,440    32,210      Selling, general and administrative43,342    49,126    88,122    96,431      Amortization of acquired intangible assets1,967    1,770    3,933    1,770      Acquisition-related charges (gains)   and product discontinuation, net1,418    3,405    (2,290)  4,647      Total operating expenses82,652    97,329    171,242    187,563    Income (loss) from operations(7,147)  5,275    9,947    6,354             Other (expense) income:          Interest income1,323    1,817    2,911    3,973      Interest expense(5,456)  (5,878)  (11,477)  (11,691)    Other, net3,969    (87)  (136)  (26)    Total other expense, net(164)  (4,148)  (8,702)  (7,744)  Income (loss) before income taxes(7,311)  1,127    1,245    (1,390)    Income tax benefit (expense)42    1,603    (356)  1,349    Net income (loss)$(7,269)  $2,730    $889    $(41)           Net income (loss) per share:          Basic net income (loss) per common share$(0.17)  $0.07    $0.02    $(0.00)    Diluted net income (loss) per common share$(0.17)  $0.06    $0.02    $(0.00)  Weighted average common shares outstanding:          Basic42,221    41,384    42,126    41,312      Diluted42,221    42,345    42,861    41,312                                      Pacira BioSciences, Inc. Reconciliation of GAAP to Non-GAAP Financial Information (in thousands, except per share amounts) (unaudited) Three Months Ended Six Months Ended  June 30, June 30,  2020 2019 2020 2019 GAAP net income (loss)$(7,269)  $2,730    $889    $(41)           Non-GAAP adjustments:          Acquisition-related charges (gains)   and product discontinuation, net1,418    3,405    (2,290)  4,647      Stock-based compensation9,222    7,783    18,070    15,217      Amortization of debt discount3,660    3,405    7,254    6,749      Amortization of acquired intangible assets1,967    1,770    3,933    1,770      Recognition of step-up basis in inventory from acquisition—    220    —    220      Income tax benefit in connection with acquisition—    (1,828)  —    (1,828)    Gain on investment(3,979)  —    (8)  —      Total Non-GAAP adjustments12,288    14,755    26,959    26,775             Non-GAAP net income$5,019    $17,485    $27,848    $26,734             GAAP basic net income (loss) per common share$(0.17)  $0.07    $0.02    $(0.00)  GAAP diluted net income (loss) per common share$(0.17)  $0.06    $0.02    $(0.00)           Non-GAAP basic net income per common share$0.12    $0.42    $0.66    $0.65    Non-GAAP diluted net income per common share$0.12    $0.41    $0.65    $0.63             Weighted average common shares outstanding - basic42,221    41,384    42,126    41,312    Weighted average common shares outstanding - diluted42,937    42,345    42,861    42,231             Cost of goods sold reconciliation:        GAAP cost of goods sold$22,305    $25,201    $52,037    $52,505      Recognition of step-up basis in inventory from acquisition—    (220)  —    (220)    Stock-based compensation(1,284)  (1,156)  (2,503)  (2,247)  Non-GAAP cost of goods sold$21,021    $23,825    $49,534    $50,038             Research and development reconciliation:        GAAP research and development$13,620    $17,827    $29,440    $32,210      Stock-based compensation(1,357)  (1,257)  (2,544)  (2,475)  Non-GAAP research and development$12,263    $16,570    $26,896    $29,735             Selling, general and administrative reconciliation:        GAAP selling, general and administrative$43,342    $49,126    $88,122    $96,431      Stock-based compensation(6,581)  (5,370)  (13,023)  (10,495)  Non-GAAP selling, general and administrative$36,761    $43,756    $75,099    $85,936        Pacira BioSciences, Inc. Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA (in thousands) (unaudited) Three Months Ended Six Months Ended  June 30, June 30,  2020 2019 2020 2019 GAAP net income (loss)$(7,269)  $2,730    $889    $(41)             Interest income(1,323)  (1,817)  (2,911)  (3,973)    Interest expense (1)5,456    5,878    11,477    11,691      Income tax (benefit) expense (2)(42)  (1,603)  356    (1,349)    Depreciation expense3,023    3,512    5,877    7,111      Amortization of acquired intangible assets1,967    1,770    3,933    1,770    EBITDA1,812    10,470    19,621    15,209             Other adjustments:          Acquisition-related charges (gains) and product   discontinuation, net1,418    3,405    (2,290)  4,647      Stock-based compensation9,222    7,783    18,070    15,217      Recognition of step-up basis in   inventory from acquisition—    220    —    220      Gain on investment(3,979)  —    (8)  —    Adjusted EBITDA (non-GAAP)$8,473    $21,878    $35,393    $35,293    (1) Includes amortization of debt discount (2) Includes an income tax benefit in connection with the April 2019 acquisition of MyoScience, Inc.Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) includes GAAP to non-GAAP adjustments that reflect how the Company’s management analyzes its financial results. The adjusted EBITDA figures presented here are unlikely to be comparable with adjusted EBITDA disclosures released by other companies. CONTACT: Investor Contact: Susan Mesco, (973) 451-4030 susan.mesco@pacira.com Media Contact: Coyne Public Relations Alyssa Schneider, (973) 588-2270 aschneider@coynepr.com

  • GlobeNewswire

    Pacira BioSciences to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

    PARSIPPANY, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference at 9:10 AM ET on Tuesday, August 11, 2020. Live audio of the virtual event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event. About Pacira                                                                           Pacira BioSciences, Inc. (NASDAQ: PCRX) is a leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for health care practitioners and their patients. The company’s long-acting local analgesic, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time.  In April 2019, the company acquired the iovera⁰ system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.Company Contact: Pacira BioSciences, Inc. Christian Pedetti (973) 254-4387 Christian.pedetti@pacira.com

  • GlobeNewswire

    Pacira Announces Publication of Phase 4 Study of EXPAREL in Cesarean Section Procedures in Anesthesia & Analgesia

    – Results show an opioid-reducing benefit of adding EXPAREL to bupivacaine transversus abdominis plane (TAP) blocks for cesarean delivery –PARSIPPANY, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that full results its Phase 4 study of EXPAREL® (bupivacaine liposome injectable suspension) administered via transversus abdominis plane (TAP) field block in patients undergoing Cesarean section (C-section) have been published in Anesthesia and Analgesia. In this study, EXPAREL achieved its primary endpoint with a statistically significant reduction in total postsurgical opioid consumption through 72 hours. EXPAREL also achieved statistical significance for reduction in percentage of opioid-spared patients through 72 hours.This was a multicenter, randomized, double-blind study across 13 clinical sites in the United States, in patients undergoing elective C-section and receiving spinal anesthesia and a multimodal analgesic regimen. Patients were randomized (1:1) to receive EXPAREL 266 mg plus bupivacaine HCl 50 mg or bupivacaine HCl 50 mg alone administered via TAP field block after delivery. Effectiveness was evaluated in a pre-specified modified intent-to-treat (mITT) population which met the study criteria regarding proper administration of TAP and multimodal regimen (N=136). Key findings include: * Significant reduction in total opioid consumption with EXPAREL plus bupivacaine HCl versus bupivacaine HCl * 52% reduction through 72 hours, the primary endpoint of the study (least squares mean [LSM] standard error [SE], 15.5 [6.67] vs 32.0 [6.25] mg, respectively; P=0.0117) * 49% reduction at one week (LSM [SE], 23.3 [9.75] vs 45.8 [9.13] mg, respectively; P=0.0175) * 41% reduction of opioid consumption at two weeks, although results did not reach statistical significance (LSM [SE], 28.2 [11.20] vs 47.8 [10.49] mg, respectively; P=0.0542) * Significantly higher percentage of opioid-spared patients with EXPAREL versus bupivacaine HCl, defined as patients who took no more than one oxycodone 10 mg tablet (or equivalent) with no opioid-related side effects through 72 hours * Percentage of opioid-spared patients was 2.2 times higher in the EXPAREL group vs bupivacaine HCl group (54% vs 25%, respectively; P=0.0012) * Optimized pain control through 72 hours, which was comparable in both groupsPatients in the EXPAREL arm of this study were administered a TAP field block with 10 mL EXPAREL admixed with 10 mL 0.25% bupivacaine HCl and 10 mL normal sterile saline injected bilaterally (for a total volume of 60 mL). Patients in the active comparator arm received a TAP field block with 10 mL 0.25% bupivacaine HCl admixed with 20 mL normal sterile saline injected bilaterally (for a total volume of 60 mL).Research shows nearly nine in 10 mothers and mothers-to-be have concerns about taking opioids during and after childbirth, yet 51% of all C-section patients are prescribed an opioid to manage postsurgical pain.“With C-sections being one of the most common surgeries in the United States, and data showing that one out of 300 opioid naïve women become persistent opioid users following cesarean delivery, it’s critical we evaluate our approach to postsurgical pain management,” said Ashraf Habib, MD, Chief, Division of Women’s Anesthesia and Professor of Anesthesiology at Duke University and study investigator. “The data from this Phase 4 study demonstrate that an EXPAREL-based multimodal regimen has the potential to optimize postoperative analgesia for C-section patients.”Prior to C-section, all patients in this study received an intrathecal injection of 150 mcg preservative-free morphine for spinal injection in conjunction with single-shot spinal anesthesia using 1.4-1.6 mL bupivacaine HCl 0.75% and 15 mcg fentanyl. Following C-section, patients also received an opioid-sparing multimodal analgesic regimen which consisted of 15 mg of intravenous (IV) ketorolac, 1000 mg of IV acetaminophen at the time of skin incision closure, and scheduled oral acetaminophen and ibuprofen beginning 6 hours after skin incision closure for up to 72 hours following surgery. Rescue medication was available upon request and postsurgical opioid consumption was collected.Safety was comparable between study groups, with 64 percent of patients in the EXPAREL group experiencing a treatment-emergent adverse event (TEAE) versus 56 percent of patients in the bupivacaine HCl group. The most common TEAEs include pruritus (itching) and nausea; serious TEAEs were rare (approximately three percent in both groups). There were no fatal TEAEs.Earlier this year, Pacira announced positive topline results for CHOICE, a next-generation C-section trial designed to eliminate the use of spinal morphine in the EXPAREL arm. In the study, EXPAREL achieved its primary endpoint with a statistically significant reduction in total opioid consumption while maintaining pain scores through 72 hours (P≤0.001), and demonstrated statistical significance for the key secondary endpoint of a reduction in the incidence and severity of itching for 72 hours after surgery (P≤0.05).About Pacira BioSciences Pacira BioSciences, Inc. (NASDAQ: PCRX) is a leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for health care practitioners and their patients. The company’s long-acting local analgesic, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time.  In April 2019, the company acquired the iovera⁰ system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.About EXPAREL EXPAREL (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks. The product combines bupivacaine with DepoFoam®, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting. By utilizing the DepoFoam platform, a single dose of EXPAREL delivers bupivacaine over time, providing significant reductions in cumulative pain scores with up to a 78 percent decrease in opioid consumption; the clinical benefit of the opioid reduction was not demonstrated. Additional information is available at www.EXPAREL.com.Important Safety Information EXPAREL is contraindicated in obstetrical paracervical block anesthesia. Adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration via infiltration were nausea, constipation, and vomiting; adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration via interscalene brachial plexus nerve block were nausea, pyrexia, and constipation. If EXPAREL and other non-bupivacaine local anesthetics, including lidocaine, are administered at the same site, there may be an immediate release of bupivacaine from EXPAREL. Therefore, EXPAREL may be administered to the same site 20 minutes after injecting lidocaine. EXPAREL is not recommended to be used in the following patient population: patients <18 years old and/or pregnant patients. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Warnings and Precautions Specific to EXPAREL: Avoid additional use of local anesthetics within 96 hours following administration of EXPAREL. EXPAREL is not recommended for the following types or routes of administration: epidural, intrathecal, regional nerve blocks other than interscalene brachial plexus nerve block, or intravascular or intra-articular use. The potential sensory and/or motor loss with EXPAREL is temporary and varies in degree and duration depending on the site of injection and dosage administered and may last for up to 5 days, as seen in clinical trials. Warnings and Precautions for Bupivacaine-Containing Products: Central Nervous System (CNS) Reactions: There have been reports of adverse neurologic reactions with the use of local anesthetics. These include persistent anesthesia and paresthesia. CNS reactions are characterized by excitation and/or depression. Cardiovascular System Reactions: Toxic blood concentrations depress cardiac conductivity and excitability which may lead to dysrhythmias, sometimes leading to death. Allergic Reactions: Allergic-type reactions (eg, anaphylaxis and angioedema) are rare and may occur as a result of hypersensitivity to the local anesthetic or to other formulation ingredients. Chondrolysis: There have been reports of chondrolysis (mostly in the shoulder joint) following intra-articular infusion of local anesthetics, which is an unapproved use. Methemoglobinemia: Cases of methemoglobinemia have been reported with local anesthetic use. Full Prescribing Information is available at www.EXPAREL.com.Company Contact: Pacira Pharmaceuticals, Inc. Susan Mesco, (973) 451-4030 Susan.Mesco@pacira.comMedia Contact: Coyne Public Relations Alyssa Schneider, (973) 588-2270 aschneider@coynepr.com